Login / Signup

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.

C R A SilveiraJ MacKinleyK ColemanZ LiE FingerR BarthaS A MorrowJ WellsM BorrieR G TironaC A RuparG ZouR A HegeleD MahuranP MacDonaldM E JenkinsM JogStephen H Pasternak
Published in: BMC neurology (2019)
ClinicalTrials.gov NCT02914366, 26 Sep 2016/retrospectively registered.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • phase iii
  • phase ii
  • study protocol
  • mild cognitive impairment
  • randomized controlled trial
  • open label
  • cognitive impairment
  • combination therapy